The Cellular State Determines the Effect of Melatonin on the Survival of Mixed Cerebellar Cell Culture

Daiane Gil Franco, Regina P. Markus*
Laboratory of Chronopharmacology, Institute of Bioscience, University of São Paulo, São Paulo, São Paulo, Brazil

Abstract

The constitutive activation of nuclear factor-κB (NF-κB), a key transcription factor involved in neuroinflammation, is essential for the survival of neurons in situ and of cerebellar granule cells in culture. Melatonin is known to inhibit the activation of NF-κB and has a cytoprotective function. In this study, we evaluated whether the cytoprotective effect of melatonin depends on the state of activation of a mixed cerebellar culture that is composed predominantly of granule cells; we tested the effect of melatonin on cultured rat cerebellar cells stimulated or not with lipopolysaccharide (LPS). The addition of melatonin (0.1 nM–1 μM) reduced the survival of naïve cells while inhibiting LPS-induced cell death. Melatonin (100 nM) transiently (15 min) inhibited the nuclear translocation of both NF-κB dimers (p50/p50, p50/RelA) and, after 60 min, increased the activation of p50/RelA. Melatonin-induced p50/RelA activity in naïve cells resulted in the transcription of inducible nitric oxide synthase (iNOS) and the production of NO. Otherwise, in cultures treated with LPS, melatonin blocked the LPS-induced activation of p50/RelA and the reduction in p50/p50 levels and inhibited iNOS expression and NO synthesis. Therefore, melatonin in vehicle-treated cells induces cell death, while it protects against LPS-induced cytotoxicity.

In summary, we confirmed that melatonin is a neuroprotective drug when cerebellar cells are challenged; however, melatonin can also lead to cell death when the normal balance of the NF-κB pathway is disturbed. Our data provide a mechanistic basis for understanding the influence of cell context on the final output response of melatonin.

Citation: Franco DG, Markus RP (2014) The Cellular State Determines the Effect of Melatonin on the Survival of Mixed Cerebellar Cell Culture. PLoS ONE 9(9): e106332. doi:10.1371/journal.pone.0106332

Editor: Hubert Vaudry, University of Rouen, France

Received January 16, 2014; Accepted August 5, 2014; Published September 3, 2014

Copyright: © 2014 Franco, Markus. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Financial support to RPM was provided by the following: São Paulo Research Foundation - FAPESP 2007/078716, National Council for Science Technology and Innovation (CNPq, 480097/2013-5), and Coordination for Support of Higher Education (CAPES-MEC). DGF is PhD fellow of FAPESP (2009/17800-4). RPM (305378/2009-0) and Débora Aparecida Moura (377855/2013-8) are senior and technical fellows of CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: rpmarkus@usp.br

Introduction

Nuclear factor kappa B (NF-κB) belongs to the Rel family that includes homo and heterodimers formed by p50, p52, RelA (p65), RelB and c-Rel. The dimers are sequestered in the cytoplasm by the inhibitory protein IκB. Various stimuli induce the complex IKK to phosphorylate the IκB that is degraded allowing NF-κB to translocate to the nucleus [1]. NF-κB is involved in the regulation of cell survival, proliferation, apoptosis and in inflammatory and immune responses [2]. In the brain, the most abundant NF-κB subunits are p50 and RelA [3]; however, c-Rel has also been detected [4]. The transcription factor NF-κB is constitutively activated in glutamatergic neurons and regulates physiological process such as cell migration, development, plasticity and synaptic transmission [5–7]. In addition, high levels of NF-κB are associated with neuropathological conditions and neurodegeneration [5,8]. Therefore, because NF-κB represents a point of convergence of several pathways (including the activation of pro- and anti-apoptotic genes), it represents a potential pharmacological target for the treatment of neurodegenerative diseases.

Melatonin, an indolamine that is derived from serotonin and that is synthesized in the pineal gland, regulates several physiological functions including circadian rhythms [9–11]. Melatonin has been shown to block the NF-κB pathway in murine macrophages [12], rat endothelial cells [13] and human neuroblastoma cells [14]. The inhibition of the nuclear translocation of NF-κB by melatonin blocks the expression of the inducible isoform of nitric oxide synthase (iNOS) and the synthesis of NO, conferring to melatonin a cytoprotective effect [12,13]. Moreover, the administration of melatonin impairs the activation of NF-κB by cytokotic substances and protects the liver and skeletal muscles by reducing the transcription of iNOS [15,16]. For these reasons, the use of melatonin has been considered for the treatment or prevention of several neurodegenerative disorders [17,18].

Not only the pineal gland can synthesize melatonin, but the brain tissue also express the key enzyme for the synthesis of melatonin, the arylalkylamine N-acetyltransferase (AA-NAT) [19–22] and there is evidence that this production is made by glial cells [22–24]. The importance of high levels of melatonin found in the central nervous system may be related to melatonin neuroprotective function [17]. The intracerebroventricular (icv) injection of lipopolysaccharide (LPS) in rats reduces nocturnal melatonin peak in the plasma and induces cell death in the hippocampus and in the cortex, but not in the cerebellum [22].

Cerebellar granule cell cultures represent a model of primary neuronal culture characterized by a basal level of NF-κB in the nucleus that is required for cell survival [3,25–27]. This culture is maintained in a partially depolarized medium that elevates...
intracellular calcium levels [28,29] and leads to proper NF-κB activation [30,31]. Thus, a disruption in the normal balance of NF-κB activity (resulting in an increase or decrease in the nuclear content of this protein) may be related to cell damage [3,6,25–27]. Given the importance of this transcription factor for neuronal cell viability and the ability of melatonin to regulate NF-κB activity, we hypothesized that the modulation of NF-κB activity by melatonin in a naïve cerebellar granule cell culture or in a culture challenged with LPS (a stimulus known to activate the NF-κB pathway) could lead to cell damage or protection.

Our data confirm that, depending on the cellular context, melatonin leads to the activation or inhibition of the nuclear translocation of NF-κB, resulting in cell death or protection, respectively. As expected, melatonin impairs the LPS-induced activation of NF-κB, the expression of iNOS and the production of NO, all of which increase cell viability. In contrast, in naïve cultures, melatonin reduces cell viability by increasing the nuclear translocation of NF-κB, the expression of iNOS and the production of NO. Because NF-κB is an integrative point of convergence of several pathways involved in both physiological and pathogenic processes, elucidating the role of melatonin in different contexts will improve our understanding of its clinical output.

**Materials and Methods**

**Animals**

Wistar rats (male and female, 7–8 days old) from the animal facility of Instituto de Biociências - University of São Paulo (IB-USP) were used according to procedures approved by IB-USP Ethical Committee (CEUA/IB license number 110/2010) in compliance with the recommendation of the National Council on Experimental Animal Control (CONCEA).

**Drugs and reagents**

Drugs and reagents purchased from Sigma-Aldrich (St. Louis, MO, EUA) included: trypsin; trypsin inhibitor; LPS from E. coli (E. coli scotype 0127:B8); melatonin, 4-(2-hydroxyethyl)-1-piperazineneethanesulfonic acid (HEPES); bis-acrilamide (N,N′-methylenebisacrylamide) and 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The following reagents were purchased from GIBCO BRL Products (Grand Island, NY, USA): Dulbecco’s modified Eagles medium (DMEM); fetal calf serum (FCS) and penicillin/streptomycin. Triton X-100 was purchased from Amresco (Solon, Ohio, USA). The following reagents were purchased from Invitrogen Life Technology (Carlsbad, CA, EUA): diithiothreitol (DTT), phenylmethylsulfonylfluoride (PMSF) and T4 polynucleotide kinase. Poly(deoxyinosinic-deoxycytidylic) acid sodium salt [poli(dIdC)] was purchased from Amersham Bioscience (Buckinghamshire, UK). Additional reagents were purchased from Bio-Rad (Richmond, CA, EUA) (acylamide), Calbiochem (Darmstadt, Germany) (Nonidet-p40 (NP40), 14000); Perkin Elmer (Boston, MA, USA) (Easy Tides: adenosine 5′-trisofosfato, [γ-32P]P); Promega (Madison, WI, USA) (Oligonucleotide consensus for NF-κB (5′-AGTTGAGGGGACTTTCCCAGGC-3′)), Molecular Probes (Eugene, OR, USA) (4-amino-3-methylamino-2′,7′dihorofluorescein diacetate (DAF-FM DA)) and IBL (Hamburg, Germany) (melatonin kit).

**Cerebellar cells culture**

The rats were decapitated and their isolated cerebella were washed, cut into small pieces and incubated in 0.05% trypsin physiological solution (NaCl 120 mM, KCl 5 mM, KH2PO4 1.2 mM, MgSO4.7H2O 1.2 mM, NaHCO3 25 mM and glucose 13 mM; pH = 7.4) at 37°C for 40 minutes. The chemical dispersion was stopped with trypsin inhibitor (0.06%) and cells that were isolated by mechanical dispersion were centrifuged (300 g, 5 min), plated in DMEM (13.4 g/L, FCS 10%, KCl 25 mM, NaHCO3 44 mM, penicillin 50 U/mL/streptomycin 50 µg/mL; 3×105–107 cells/well) and maintained at 37°C, 5% CO2. Every 48 hours 50% of the medium was changed. Experiments were conducted on the seventh or eighth days of in vitro culture, and the medium was changed at least one hour before treatment.

The immunofluorescence staining using antibodies against MAP-2 (neuron marker), GFAP (astrocyte marker) and ED-1 (microglia marker) indicated that the cellular composition of the culture was 80–90% neurons, 10–15% astrocytes and 2–3% microglia. This culture is similar to that described by Kawamoto et al. [32] and Ohashi et al. [33].

**Experimental Protocols**

The nuclear translocation of NF-κB was examined in cerebellar cell cultures challenged with LPS (100 ng/mL) for 15, 30 or 60 minutes in the presence or absence of melatonin (10 nM–1 µM). Cellular viability was assessed in cultures that were challenged with LPS (30–300 ng/mL) in the presence or absence of melatonin (10 nM–1 µM) for 24 hours. An iNOS activity inhibitor (1400W, 1 µM) was added to the culture 30 minutes before treatment with LPS or melatonin. The expression of iNOS was measured in cultures that were incubated with melatonin (10 nM–1 µM), LPS (100 ng/mL) or both for one hour. The production of nitric oxide was measured in cultures that were treated with LPS (100 ng/mL), melatonin (100 nM) or both for 24 hours. In all of the experiments, the control group was treated with a melatonin vehicle (ethanol 0.005%) and/or LPS vehicle (medium).

**Cell viability**

Cell viability was assessed in cerebellar cell cultures using the MTT (a yellow tetrazole) method. MTT was added to cells at a final concentration of 0.005 g/mL and incubated for two hours to allow the reduction of MTT (which results in the formation of dark blue formazan crystals). The crystals were dissolved in dimethyl sulfoxide (DMSO) for 30 minutes in a shaker. Formazan production was measured by the change in absorbency at 540 nm using a microplate reader (SpectraMax 250, Molecular Devices, Sunnyvale, CA). Viability results were expressed as percentages of the absorbency measured in control cells.

**Electromobility-shift assay (EMSA)**

Nuclear proteins were extracted from the cultures according to the method described by Ferreira et al. [34]. Briefly, the cultures were homogenized in lysis buffer (HEPES 10 mM, KCl 10 mM, EDTA 0.1 mM, DTT 1 mM, PMSF 0.1 mM), centrifuged (12000 g, 1 min) twice and resuspended in extraction buffer (HEPES 10 mM, KCl 500 mM, EDTA 1 mM, DTT 1 mM, PMSF 0.1 mM). After 15 minutes of incubation on ice and centrifugation (20000 g, 5 min), the supernatant containing the nuclear proteins was collected in new microtubes and stored at −20°C. The total nuclear protein concentration was quantified at 280 nm using a ND-1000 spectrophotometer (NovoDrop, Wil-
mington, DE, USA). Six micrograms of protein were incubated in a final volume of 15 μL of binding buffer (Tris-HCl 10 mM pH 7.5; MgCl₂ 1 mM; NaCl 50 mM; DTT 0.5 mM; EDTA 0.5 mM; glycerol 4%; poli-dIdC 1 μg) for 20 minutes at room temperature. Approximately 40,000 counts/min of double-stranded oligonucleotide probes containing the NF-κB consensus sequence (5‘AGTTGAGGGGACTTTCCCAGGC) labeled with γ-ATP-32P were added for 30 minutes at room temperature. The protein-DNA complexes were analyzed in non-denaturant 6% polyacrylamide gel at 150 V for 1.5 hours in tris-borato/EDTA buffer (TBE). After drying, the gel was exposed to a XAR-5 Kodak film (Rochester, NY, USA) for 48–72 hours at −80°C. Autoradiograms were analyzed densitometrically using the program ImageJ (Image Processing and Analysis in Java).

To identify NF-κB subunits, non-stimulated cells were incubated with 2 μg/mL of rabbit polyclonal affinity purified antibodies against p50, p52, RelA, RelB and c-Rel for 45 minutes at room temperature, before the addition of 32P-NFKB probe. EMSA was carried out as described previously.

### iNOS immunofluorescence

The expression of iNOS was measured according to an adapted protocol of Ferrari et al. [35]. The cells were washed with phosphate saline solution (PBS: NaCl 125 mM, Na₂HPO₄ 2 mM, NaH₂PO₄ 2 mM, KCl 5 mM) and fixed in methanol/acetone (1:1, 15 min, 20°C). The cells were washed three times with phosphate saline and incubated for 30 minutes at room temperature with 0.2% Triton X-100 diluted in PBS. The preparation was incubated with anti-iNOS TRITC-conjugated antibodies (1:50, Triton X-100 (0.2%)) and kept overnight at 4°C. The cells were then washed three times in PBS and the slides were mounted with PBS and glycerol (1:1). The fluorescence was analyzed with an inverted confocal laser-scanning microscope equipped with a 40× oil-immersion objective (LSM 500, Carl Zeiss, New York, NY, USA) using the HeNe laser (543 nm) for excitation. To quantify the fluorescence, the LSM510 software (Carl Zeiss, LSM510) was used; only the granule cells identified and differentiated from other cell types by their morphology were considered. Five images containing 25–40 granule cells were randomly chosen and imaged as a 1024×1024-pixel frame; all of the other settings, including the pinhole, scanning speed and laser power, remained the same for all experiments. Inducible-NOS expression was evaluated as the percentage over the mean of the vehicle group.

### Nitric oxide

The level of NO was determined using the fluorescent indicator DAF-FM DA (5 μM), as previously described by Tamura et al. [36]. The cells were incubated in physiological solution (NaCl 140 mM, KCl 5 mM, MgCl₂ 1 mM, CaCl₂ 2 mM, glucose 5 mM, HEPES 5 mM, L-arginine 100 μM; pH 7.4) and treated for 24 hours with melatonin (100 nM) in the presence or absence of LPS (100 ng/mL). The control group received only the vehicle. The cells were incubated at room temperature for 30 minutes with 5 μM DAF-FM DA. The fluorescent compound was excited with an argon laser (488 nm) and the emitted fluorescence was measured at 515–530 nm using an inverted confocal laser-scanning microscope equipped with a 40× oil-immersion objective (LSM 500, Carl Zeiss, New York, NY, USA). The quantification of fluorescence was performed using the protocol described for iNOS expression. Nitric oxide levels were expressed as the percentage over the mean of the vehicle group.

### Statistical analyses

Data expressed as percentages of the vehicle were reported as the mean ± S.E.M. Results were compared by one-way analysis of variance (ANOVA) and the Newman-Keuls post-test.

### Results

The results of the MTT assay showed that LPS (30–300 ng/mL, 24 h) reduced the survival of cultured cerebellar cells by up to 40% (fig. 1A). Melatonin (0.1 nM–1 μM, 24 h) protected the cells against LPS (fig. 1B). Surprisingly, the control group incubated with melatonin (100 nM–1 μM, 24 h) experienced a 20% reduction in cell viability (fig. 1B), suggesting that, in the absence of LPS, melatonin itself can reduce cell viability. Because NF-κB is a common target for melatonin and LPS and cerebellar cells require a basal level of NF-κB activation for neuronal survival [3], we evaluated whether this central transcription factor involved in programming defense responses and neuronal survival could be involved in these conflicting effects of melatonin.

The transcription factor NF-κB is constitutively expressed in control cultures, as demonstrated by the results of the EMSA analysis (fig. 2A): antibodies against p50 and RelA identified p50/p50 and p50/RelA dimers, as the p50 antibody shifted both complexes but RelA shifted only the first complex. The other antibodies that were tested (p52, RelB and cRel) did not shift any complexes (data not shown).

The incubation of the cultures with 100 nM melatonin induced a transient reduction in the nuclear level of p50/p50 and p50/RelA dimers during the first 15 minutes (fig. 2B). After 30 minutes of incubation, the nuclear levels of both NF-κB dimers were restored to their initial values; after 60 minutes of incubation, the nuclear content of p50/RelA (but not of p50/p50) was significantly increased. Because melatonin directly reduced levels of nuclear NF-κB within 15 min, we used this time interval to construct melatonin dose-response curves (fig. 2C). The maximal reduction in NF-κB content induced by melatonin (40%) was similar for both dimers; however, p50/RelA levels were reduced to a greater extent than p50/p50, indicating a specific sensitivity for each dimer. In summary, in cultured cerebellar cells melatonin produces a transient reduction in the nuclear content of both NF-κB dimers, followed by an increase of the p50/RelA nuclear activity above basal levels.

The addition of LPS (100 ng/mL, 15 min) significantly increased and decreased the nuclear content of p50/RelA and p50/p50, respectively (fig. 2D). Melatonin (10 nM–1 μM) blocked the LPS-induced nuclear translocation of p50/RelA but did not interfere with the reduction in levels of p50/p50, although the higher concentration of melatonin (1 μM) tended to increase levels of p50/p50 towards baseline levels. Therefore, in the presence of LPS, melatonin reduced NF-κB nuclear activity. The opposing effects of melatonin observed in naïve and LPS-treated cultures incubated for 60 minutes was in agreement with the dual effect on cell survival described in figure 1. The hypothesis of opposing effects was tested by evaluating phenotypic outputs (iNOS expression and NO production) and cell survival in the presence of the selective iNOS inhibitor 1400W.

The expression of iNOS in granule cells was evaluated by immunocytochemistry (fig. 3). The granule cells were identified by their rounded morphology and relatively small size (indicated by black arrows). Other cells with differentiated morphology (indicated by white arrow heads) were not quantified. Inducible-NOS was detected to be constitutively activated in the naïve group (fig. 3A). The addition of melatonin or LPS increased iNOS expression (fig. 3B, C, 4A). When melatonin was incubated with
Figure 1. Dual effect of melatonin on the viability of cultured cerebellar cells. (A) Viability concentration-response curve for cells treated with LPS (30–300 ng/mL) incubated for 24 h; (B) Viability concentration-response curve for cells treated with melatonin (0.1 nM–1 μM) in the presence or absence of LPS (100 ng/mL), incubated for 24 hours. Each well contained 10^5 cells at the beginning of the experiment. * p < 0.05; **p < 0.01 compared to control (n = 8–10 per point). doi:10.1371/journal.pone.0106332.g001

Figure 2. Activation of nuclear factor-kappa B (NF-κB) in cultured cerebellar cells. (A) Super-shift assay performed with nuclear extracts from naive cultured cerebellar cells incubated with antibodies against p50 and RelA subunits. The super-shift indicates the presence of the dimers p50/p50 and p50/RelA. (B) Time course for NF-κB activation by melatonin (100 nM) showing a transient reduction in the nuclear content of p50/p50 and p50/RelA followed by a significant increase in the nuclear content of p50/RelA (C) Concentration-response curve for melatonin (10 nM–1 μM, 15 min). (D) LPS (100 ng/mL, 15) induced NF-κB nuclear translocation in the presence or absence of melatonin (10 nM–1 μM, 15 min). For quantification the whole experiment present in graphs B, C and D was done in one gel, repeated 5 to 8 times. The values are expressed as percentage of the image detected in control conditions. * p < 0.05% compared to control and # p < 0.05 compared to LPS group (n = 5–8 per point). Symbols – squares: p50/RelA; triangles: p50/p50.

doi:10.1371/journal.pone.0106332.g002
LPS, the expression of the enzyme was reduced to levels similar to those observed in the naïve group (fig. 3D, 4A).

As predicted, LPS (100 ng/mL, 60 min) increased the expression of iNOS, while all of the concentrations of melatonin (30–300 nM) inhibited this effect of LPS (fig. 4A). The addition of melatonin in naïve cultures promoted a transient reduction in the expression of iNOS (30 min); however, after 120 minutes, iNOS levels were restored to levels slightly above basal levels (fig. 4B). Lipopolysaccharide induced an increase in iNOS expression above basal values within 30 minutes and this effect was blocked by melatonin (fig. 4B). Therefore, the effect of melatonin on iNOS expression was similar to that observed for the translocation of NF-kB.

As a result of the increase in iNOS expression, the incubation of cells with LPS (100 ng/mL, 24 h) or melatonin (100 nM, 24 h) led to an increase in the production of NO. In addition, melatonin blocked LPS-induced NO production (fig. 5A). The reduction in cell survival that was induced by LPS (100 ng/mL, 24 h) and melatonin (100 nM, 24 h) was not observed when the activity of iNOS was blocked by the selective antagonist 1400W (1 μM) (fig. 5B,C). Moreover, the blockage of iNOS activity increased cell survival in naïve cultures, indicating that the survival of this culture depends on the constitutive activity of iNOS.

**Discussion**

Melatonin has been described as a cytoprotective and prosurvival agent that acts through both membrane receptor-dependent and independent mechanisms [11]. In this study, melatonin was confirmed to have a cytoprotective effect in cultures of cerebellum, which contains a majority of granule cells, incubated with LPS. Surprisingly, we also found that melatonin had a neurotoxic effect in cultures incubated without LPS.

The cerebellum, which is a target of melatonin G-protein coupled receptors [37–40], was used as a classical model to study the protective effect of melatonin against hyperbaric oxygen exposure [41], lipid peroxidation [42,43], glutamate-induced neurotoxicity [44], aluminum exposition [45] and hypoxia [46]. Melatonin was shown to interfere with cerebellar tissue by inhibiting glutamate release [47], the transient outward flow of potassium [48], nicotinic currents [49] and the migration of granule cells [50]. Moreover, in rats the administration of LPS (icv) leads to the synthesis of melatonin in the cerebellum, but not in the hippocampus and cortex [22]. Even more, pinealectomy zeroed the content of melatonin in the cortex and hippocampus of LPS (icv) treated rats, while the level of melatonin in the cerebellum remains higher than those detected in animals killed at nighttime. The local synthesis of melatonin in the cerebellum was responsible for impairing cerebellar neuronal death.

**Figure 3.** Representative confocal microscopy image of immunocytochemistry for iNOS expression in cultured cerebellar cells. (A) Control, (B) incubation with 100 nM melatonin for 60 min, (C) incubation with 100 ng/mL LPS for 60 min and (D) incubation with melatonin + LPS. Black arrows indicate granule cells and white arrow heads indicate other types of cells (glial cells).

doi:10.1371/journal.pone.0106332.g003

**Figure 4.** Quantification of the expression of iNOS.

(A) LPS (100 ng/mL, 60 min) induced the expression of iNOS in the presence or absence of melatonin (30–300 nM, 60 min) (B) Time course of cells cultured with melatonin (100 nM), LPS (100 ng/mL) and melatonin + LPS. * p<0.05 and ** p<0.01 compared to control and ≠ p<0.05 compared to LPS group (n = 4–6 per point). The number of cases refers to independent samples obtained in different days and from different cultures.

doi:10.1371/journal.pone.0106332.g004
The cerebellar granule cell culture requires elevated levels of potassium [28,29,51,52] that increases intracellular calcium. The constitutive activity of NF-κB, that is necessary for maintaining cerebellar granule cell in vitro [3,25–27], is consecutive of calcium entry into the cytosol [30]. An unbalance of NF-κB activity, in turn, leads to cell death [3,7]. In this study, we examined the effect of melatonin on the viability of cerebellar cells in culture through modulation of the transcription factor NF-κB. Depending on the cellular context, the incubation of the culture with melatonin can result either in an increase or a decrease in the nuclear content of the p50/RelA subunit. This subunit contains the transactivating domain responsible for the transcription of the package of genes involved in cell defense, including the gene of iNOS. Therefore, an increase in the nuclear content of p50/RelA results in the production of NO and cell death.

We confirmed that cerebellar granule cells challenged by LPS express iNOS and produce NO [53]. Although we evaluated the expression of iNOS and NO production in granule cells, we can not ignore an indirect effect of LPS or melatonin through activation of glial cells in the culture. Despite the bidirectional interaction between glia and neurons is not yet well understood, it is known that the presence of glia in culture is needed to protect neurons [54]. The indirect effect of LPS was demonstrated in the pineal gland [55]. Although the main cell types of the pineal gland (pinealocytes, astrocytes and microglia) express TLR4, the production of TNF induced by LPS is mediated by microglia. The cytokine produced inhibits the synthesis of melatonin by pinealocytes.

The present study corroborated the results of several studies that demonstrated the beneficial effects brought about by the melatonin-mediated inhibition of NF-κB nuclear activity in vivo [15,16,36,57] and in vitro [12,13,58]. The reduction in cellular viability observed in non-treated cells was most likely the result of an increase in the nuclear translocation of p50/RelA and therefore of the expression of iNOS and the production of NO resulting from a long-term incubation with melatonin. It is interesting to note that a melatonin-induced increase in reactive oxygen species (ROS) has been described in cancer cells [59–62] and appears to be associated with a reduction in tumor growth and proliferation. In addition, melatonin was shown to have a pro-oxidant effect that is mediated by an increase in NF-κB activity in a promonocytic cell line (U937) [63].

The present study shows that in non-treated cells melatonin inhibits the activation of NF-κB in the short-term, which tends to have a cytoprotective effect. The mechanism behind this effect likely involves the fine-tuned modulation of the NF-κB pathway by NO in a feedback loop. The NF-κB pathway is downregulated by an increased production of NO. The activation of neuronal NO or pretreatment with NO donors inhibits the LPS- or tumor necrosis factor (TNF)-induced nuclear translocation of NF-κB [64–67]. The basic mechanism underlying this functional output involves the nitrosylation or nitration of key molecules in the NF-κB pathway. The S-nitrosylation of IKK impairs the activation of NF-κB [68]; in addition, the tyrosine nitration of RelA maintains this subunit in the cytoplasm [69] and the s-nitrosylation of p30 impairs the binding of homo and heterodimers to DNA [70,71]. Nitric oxide also induces and stabilizes the NF-κB inhibitory protein IkBα [65]. Therefore, if the basal level of NO is reduced below a critical value, the loss of nitrosylation or nitration favors the activation of NF-κB and leads to an increase in iNOS expression and NO production. Our results therefore suggest that in naive cultures melatonin reduces the nuclear level of NF-κB below basal values, resulting in a decrease in iNOS and NO that is sufficient to induce subsequent NF-κB activation. This increase only occurred with the transcriptional activator p50/RelA complex and not the inhibitory complex p50/p50, which results in the increased gene expression and reduced gene suppression. Thus, because iNOS expression is controlled by NF-κB, the addition of melatonin ultimately results in an increase in iNOS expression and NO production and a resultant reduction in cell survival. This hypothesis was confirmed by blocking melatonin-induced cell death with an inhibitor of iNOS activity. However, when cultured cerebellar cells are challenged by LPS, melatonin balanced the NF-κB activation generating cell protection.

In summary, we confirmed that melatonin can protect cerebellar cells that are challenged by a stimulus such as LPS; however, it can also induce a fatal loss in the normal balance of the NF-κB pathway. Thus, our data describe the mechanism behind the influence of the cell context on the final effect of melatonin.
Acknowledgments

The authors are indebted with Débora Aparecida Moura for her technical assistance.

References

1. Xiao W (2004) Advances in NF-xB signaling transduction and inhibition. Cellular & Molecular Immunology 1: 425–433.
2. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 15: 2195–2224.
3. Kaltschmidt B, Widersa D, Kaltschmidt C (2005) Signaling via NF-xB in the nervous system. Biochimica et Biophysica Acta 1745: 267–299.
4. Pizzi M, Spasso P (2006) Distinct roles of diverse nuclear factor-xB complexes in neuropathological mechanisms. Eur J Pharmacol 545: 22–28.
5. Grilli M, Memo M (1999) Nuclear Factor-xB/Rel Proteins: A point of convergence of signaling pathway relevant in neuronal function and dysfunction. Biochem Pharmacol 57: 1–7.
6. Malek R, Borowiec KK, Jorgelino M, Cruzevic SJ (2007) Role of nuclear factor kappaB in the central nervous system. Pharmacol Rep 59: 25–33.
7. Kaltschmidt B, Kaltschmidt C (2009) NF-xB in the nervous system. Cold Spring Harb Perspect Biol 1: a001271.
8. Pizzi M, Sarnicco L, Lanzilotta A, Battistin I, Spasso P (2009) Post-ischemic brain damage: NF-xB dimer heterogeneity as a molecular determinant of neuron vulnerability. FEBS J 276: 27–35.
9. Reiter RJ, Tan DX, Manchester LC, Tamura H (2007) Melatonin defeats neuronal-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J Physiol Pharmacol 58: 5–22.
10. Ortiz GG, Benitez-King GA, Rosales-Corral AS, Pacheco-Moisés FP, Velezquez-Brizuela II (2006) Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr Neuropharmacol 6: 203–214.
11. Luchetti F, Canonicob F, Betti M, Arcangeletti M, Pilollib F, et al. (2010) Melatonin signaling and cell protection function. FACEB 24: 3063–3064.
12. Gibellini F, Song H, Zungarelli B, Vira´g L, O'Connor M, et al. (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF-xB activation. FACEB 12: 683–693.
13. Tamura EK, Ceccon E, Monteiro AW, Silva CB, Markus RP (2009) Melatonin inhibits LPS-induced NO production in rat endothelial cells. J Physiol 586: 268–274.
14. Lezoualch F, Sparapani M, Belc (1996) N-acetyl-serotonin (narmelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-xB. J Neurosci 23: 1689–1707.
15. Bruck R, Ariel H, Avni Y, Sharon H, Matas Z, et al. (2004) Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol 40: 86–93.
16. Alonso M, Collado PS, Gonzales-Gallego J (2006) Melatonin inhibits the expression of the inducible isoform of nitric oxide synthase and nuclear factor kappa B activation in rat skeletal muscle. J Physiol Res 41: 8–14.
17. Hardeland R (2012) Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. Scientific World Journal 2012: 640389.
18. Pandi-Perumal SR, Uz T, Dzitoyeva S, Giusti P, Manev H (2008) Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors. Brain Res 1227: 19–25.
19. Adaham-Biass E, Zhang Y, Jung H, Vissapragada S, Muller R, et al. (2015) Distribution of MT1 Melatonin Receptor Promoter-Derived RFP Expression in the Brains of BAC C3H/HeN Transgenic Mice. J Histochem Cytochem In press.
20. Pahlos MI, Reiter RJ, Chauang JI, Ortiz GG, Guerrero JR (1997) Acutely administered melatonin reduces oxidative damage in lung and brain induced by hyperbaric oxygen. J Appl Physiol (1985) 83: 334–338.
21. Princ FG, Jukat NA, Maxit AG, Cardalda C, Baille A (1997) Melatonin's anti-inflammatory protection against delta-aminolevulinic acid-induced oxidative damage in rat cerebellum. J Pineal Res 25: 49–56.
22. Carneiro RC, Reiter RJ (1998) Melatonin protects against lipid peroxidation induced by delta-aminolevulinic acid in rat cerebellum, cortex and hippocampus. Neurobiol 82: 293–299.
23. Gendre-Brejane A, Daizueri S, Hacimutufooglu A, Bulcado D, Suleymen H (2000) The effects of melatonin in glutamate-induced neurotoxicity of rat cerebellar granule cell culture. Jpn J Pharmacol 84: 467–469.
24. Esparriza JL, Gómez M, Rosa Nogués M, Paternain JM, Mallol J, et al. (2005) Melatonin reduces oxidative stress and increases gene expression in the cerebral cortex and cerebellum of aluminum-exposed rats. J Pineal Res 39: 129–136.
25. Kaur C, Vela´zquez-Brizuela IE (2008) Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr Neuropsychopharmacol 6: 203–214.
26. Liu YJ, Zhang J, Zhu HY, Shen YX, Tan ZL, et al. (2007) Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J Pineal Res 43: 232–238.
27. Tan DX, Manchester LC, Sanchez-Barcelo, Medaivilla MD, Reiter RJ (2010) Significance of high levels of endogenous melatonin in Mammalian cerebrospinal fluid and in the central nervous system. Curr Neuropharmacol 8: 162–167.
28. Piccoli P, Porcile C, Stanzione S, Bisaglia M, Bajetto A, et al. (2001) Inhibition of nuclear factor-kappaB small activation induces apoptosis in cerebellar granule cells. J Neurosci Res 66: 1064–1073.
29. Bhakar AL, Tannis LL, Zeindler C, Russo MP, Jobin C, et al. (2002) Constitutive nuclear factor-kappaB activity is required for central neuron survival. J Neurosci 22: 4366–4373.
30. Fritschner V, Kaltschmidt B, Goudeau B, Ndiaye D, Rossi FM, et al. (2003) Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J Neurosci 23: 9403–9408.

Author Contributions

Conceived and designed the experiments: DGF RPM. Performed the experiments: DGF RPM. Analyzed the data: DGF RPM. Contributed reagents/materials/analysis tools: RPM. Wrote the paper: DGF RPM.
54. Polazzi E, Gianni T, Contestabile A (2001) Microglial cells protect cerebellar granule neurons from apoptosis: evidence for reciprocal signaling. Glia 36: 271–280.

55. da Silveira Cruz-Machado S, Pinato L, Tamura EK, Carvalho-Sousa CE, Markus RP (2012) Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS One 7: e40142.

56. Tripathi DN, Jena GB (2010) Effect of melatonin on the expression of Nrf2 and NF-kappaB during cyclophosphamide-induced urinary bladder injury in rat. J Pineal Res 48: 324–331.

57. Bekyarova G, Apostolova M, Kotzev I (2012) Melatonin protection against burn-injured hepatic injury by down-regulation of nuclear factor kappa B activation. Int J Immunopathol Pharmacol 25: 591–596.

58. Min KJ, Jang JH, Kwon TK (2012) Inhibitory effects of melatonin on the lipopolysaccharide-induced CC chemokine expression in BV2 murine microglial cells are mediated by suppression of Akt-induced NF-kappaB and STAT/GAS activity. J Pineal Res 52: 296–304.

59. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, et al. (2003) Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60: 1407–1426.

60. Blask DE, Dauchy RT, Sauer LA (2005) Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27: 179–188.

61. Bejarano I, Espino J, Barriga C, Reiter RJ, Pariente JA, et al. (2011) Pro-oxidant effect of melatonin in tumor leucocytes: relation with its cytotoxic and pro-apoptotic effects. Basic Clin Pharmacol Toxicol 108: 14–20.

62. Hill SM, Blask DE, Xiang, Yuan L, Mao L, et al. (2011) Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia 16: 235–245.

63. Cristofanon S, Ugazzioni F, Cerella C, Radegna F, Dicato M, et al. (2009) Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kappaB activation. Ann N Y Acad Sci 1171: 472–478.

64. Park SK, Lin HL, Murphy S (1994) Nitric oxide limits transcriptional induction of nitric oxide synthase in CNS glial cells. Biochem Biophys Res Commun 201: 762–768.

65. Peng HB, Labby P, Liao JK (1995) Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappaB. J Biol Chem 270: 14214–14219.

66. Colasanti M, Persichini T, Menegazzi M, Marzotto S, Giordano E, et al. (1995) Induction of nitric oxide synthase mRNA expression. Suppression by exogenous nitric oxide. J Biol Chem 270: 26731–26733.

67. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, et al. (1997) Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci USA 94: 2676–2680.

68. Reynaert NL, Cikless K, Korn SH, Vos N, Guala AS, et al. (2004) Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci USA 101: 8945–8950.

69. Park SW, Hsu MD, Hu X, Wei LN (2005) Tyrosine nitration on p65: a novel mechanism to rapidly inactivate nuclear factor-kappaB. Mol Cell Proteomics 4: 300–306.

70. Matthews JR, Botting CH, Panico M, Morris HR, Huy RT (1998) Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res 24: 2236–2242.

71. Delatorre A, Schroeder RA, Punzalan C, Kuo PC (1999) Endotoxin-mediated S-nitrosylation of p50 alters NF-kappaB-dependent gene transcription in ANA-1 murine macrophages. J Immunol 162: 4101–4108.